Skip to main content

Per fare trading negli USA, vai su polymarket.us

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tecnologia·Corea Del Sud

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tecnologia·Corea Del Sud

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% probabilità
Polymarket

$11,414 Vol.

13% probabilità
Polymarket

$11,414 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414
Data di fine
7 ott 2026
Mercato aperto
May 5, 2026, 8:02 PM ET

Risolutore

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414
Data di fine
7 ott 2026
Mercato aperto
May 5, 2026, 8:02 PM ET

Risolutore

0x65070BE91...

Correlati

icon for Domanda di autorizzazione (BLA) per il vaccino contro il cancro della pelle presentata entro il 30 giugno 2027?

Domanda di autorizzazione (BLA) per il vaccino contro il cancro della pelle presentata entro il 30 giugno 2027?

88%
Sì
icon for La FDA approverà Retatrutide quest'anno?

La FDA approverà Retatrutide quest'anno?

3%
Sì
icon for Vaccino contro il cancro della pelle approvato dalla FDA entro il 31 dicembre 2027?

Vaccino contro il cancro della pelle approvato dalla FDA entro il 31 dicembre 2027?

65%
Sì

Fai attenzione ai link esterni.

Domande frequenti

"Eli Lilly licenses Peptron’s SmartDepot by October 7?" è un mercato predittivo su Polymarket dove i trader comprano e vendono azioni "Sì" o "No" in base a se credono che questo evento accadrà. La probabilità attuale aggregata è 13% per "Yes". Ad esempio, se "Sì" è quotato a 13¢, il mercato assegna collettivamente una probabilità di 13% che questo evento si verifichi. Queste quote cambiano continuamente man mano che i trader reagiscono a nuovi sviluppi e informazioni. Le azioni nell'esito corretto possono essere riscattate per $1 ciascuna alla risoluzione del mercato.

Ad oggi, "Eli Lilly licenses Peptron’s SmartDepot by October 7?" ha generato $11.4K in volume totale di trading dal lancio del mercato il May 5, 2026. Questo livello di attività di trading riflette un forte coinvolgimento della comunità Polymarket e contribuisce a garantire che le quote attuali siano informate da un ampio pool di partecipanti al mercato. Puoi seguire i movimenti di prezzo in tempo reale e fare trading su qualsiasi esito direttamente su questa pagina.

Per fare trading su "Eli Lilly licenses Peptron’s SmartDepot by October 7?", scegli semplicemente se ritieni che la risposta sia "Sì" o "No". Ogni lato ha un prezzo corrente che riflette la probabilità implicita del mercato. Inserisci il tuo importo e clicca "Trading". Se compri azioni "Sì" e l'esito si risolve come "Sì", ogni azione paga $1. Se si risolve come "No", le tue azioni "Sì" pagano $0. Puoi anche vendere le tue azioni in qualsiasi momento prima della risoluzione se vuoi consolidare un profitto o limitare una perdita.

La probabilità attuale per "Eli Lilly licenses Peptron’s SmartDepot by October 7?" è 13% per "Yes". Questo significa che la comunità Polymarket attualmente ritiene che ci sia una probabilità di 13% che questo evento si verifichi. Queste quote si aggiornano in tempo reale basandosi sulle operazioni effettive, fornendo un segnale continuamente aggiornato di ciò che il mercato si aspetta accada.

Le regole di risoluzione per "Eli Lilly licenses Peptron’s SmartDepot by October 7?" definiscono esattamente cosa deve accadere affinché ogni esito venga dichiarato vincitore — comprese le fonti di dati ufficiali utilizzate per determinare il risultato. Puoi consultare i criteri completi di risoluzione nella sezione "Regole" di questa pagina sopra i commenti. Ti consigliamo di leggere attentamente le regole prima di fare trading, poiché specificano le condizioni precise, i casi limite e le fonti che regolano come viene risolto questo mercato.